Clinical Trials Browser

Pathologic Complete Response, Carcinoma, Non-Small-Cell Lung

Ann Arbor Stage II Mantle Cell Lymphoma

Uterine Cervical Neoplasms

Urinary Bladder Neoplasms

Thymic epithelial tumor, Mediastinal Neoplasms, Thymoma

Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

Esophageal Squamous Cell Carcinoma

Carcinoma, Non-Small-Cell Lung

Advanced Squamous Non-Small Cell Lung Cancer

Ovarian Neoplasms

Mesothelioma, Malignant

Esophageal Squamous Cell Carcinoma

Squamous Cell Carcinoma of Head and Neck

Squamous Cell Carcinoma of Head and Neck

Biliary Tract Neoplasms

Non Squamous Non-small Cell Lung Cancer

Nasopharyngeal Neoplasms

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms

Advanced Biliary Tract Cancer(BTC)

Squamous Cell Carcinoma of Head and Neck

Nasopharyngeal Neoplasms

Carcinoma, Non-Small-Cell Lung

Lymphatic Metastasis

Liver Neoplasms

HER2-positive Gastric Cancer

Sarcoma, Ewing, Osteosarcoma

Uterine Cervical Neoplasms

Neoplasm Metastasis

Carcinoma, Non-Small-Cell Lung, Neoplasms, Disease Progression

Carcinoma, Non-Small-Cell Lung

Uterine Cervical Neoplasms

Nasopharyngeal Cancinoma (NPC)

Extensive Stage Lung Small Cell Cancer

Uterine Cervical Neoplasms

Urinary Bladder Neoplasms

Uterine Cervical Neoplasms

Nasopharyngeal Carcinoma

CLDN18.2-positive Advanced Biliary Tract Cancer

Head and Neck Cancer Squamous Cell Carcinoma

Nasopharyngeal Carcinoma, Epstein-Barr Virus Infections

Nasopharyngeal Carcinoma

Glioblastoma

Squamous Cell Cancer of Head and Neck (SCCHN)

Biliary Tract Neoplasms

Nasopharyngeal Carcinoma

Extensive Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

Esophageal Neoplasms

Bile Duct Neoplasms, Biliary Tract Neoplasms, Cholangiocarcinoma, Klatskin Tumor

Clinical Trials

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma

Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer

TRIFECTA

6 vs 3 Cycles of Neoadjuvant Chemotherapy for Potentially Resectable Locally Advanced Thymic Epithelial Tumors

QLS5132 Combination Therapy in Advanced Solid Tumors

Time-of-Day of Immunotherapy Infusion in Neoadjuvant Immunochemotherapy for Thoracic ESCC

FANLUNG-2：The Value of High-Low Mixed-Dose Radiotherapy Combined With Chemo-Immunotherapy Induction in Locally Advanced Non-Small Cell Lung Cancer

CECYDE

Iparomlimab and Tuvonralimab (QL1706) Combined With Standard Chemotherapy or Combined With Intraperitoneal Perfusion Chemotherapy and Olaparib as Neoadjuvant Therapy for Advanced Ovarian Cancer

LAG-MAPS

Short-course Radiotherapy Combined With Serplulimab and Chemotherapy as Neoadjuvant Treatment for Resectable ESCC

Intralesional Chemotherapy (IC): Cisplatin + Epinephrine

Neoadjuvant Becotatug Vedotin Plus Pucotenlimab and Cisplatin for Locally Advanced Head and Neck Squamous Cell Carcinoma

Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer

Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer

Anlotinib Plus Immunotherapy and Chemoradiotherapy for High-Risk Nasopharyngeal Carcinoma

PDT For Induction Therapy For Head And Neck Cancer

NOBLE

SHINE

Short-course Tislelizumab Combined With Chemoradiotherapy for Nasopharyngeal Carcinoma

TeLuRide-008

Propranolol With Tislelizumab Plus GC in Neoadjuvant Bladder UC

Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy and Sequential Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer

A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinoma

A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer

Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma

HypoRTCx-UG

Study of ISM5939 in Patients With Advanced and/or Metastatic Solid Tumors

HYPERBOLIC

A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous Non-small Cell Lung Cancer

Neoadjuvant Ivonescimab Plus Chemotherapy Followed by Concurrent Chemoradiotherapy in High-Risk Locally Advanced Cervical Cancer

Phase III Trial of EBV-DNA-Guided Adaptive Immunotherapy for Advanced Nasopharyngeal Carcinoma

Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung Cancer

Clinical Study to Evaluate the Efficacy and Safety of Nab-Paclitaxel Combined With Cisplatin and Sintilimab in Neoadjuvant Treatment of Locally Advanced Cervical Cancer

No Acronym

A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy of KRC-01

Perioperative Chemotherapy and Immunotherapy for Locally Recurrent Nasopharyngeal Carcinoma

Combination of QLS31905 and Chemotherapy ± QL2107 in Patients With CLDN18.2-positive Advanced Biliary Tract Cancer

Neoadjuvant Immunochemotherapy and Postoperative Adjuvant Immunotherapy for Head and Neck Squamous Cell Carcinoma Invading the Skull Base

EBV Lytic Reactivation Therapy Combined With PD-1 Antibody in Recurrent/Metastatic Nasopharyngeal Carcinoma

Toripalimab, Induction Chemotherapy, Radiation Therapy With Omega-3 for Locally Advanced Nasopharyngeal Carcinoma

Phase 2 Clinical Trial of KH617

Comparing Postoperative Adjuvant Cisplatin Concurrent Chemoradiotherapy With Adjuvant Radiotherapy Alone for Intermediate-risk Head and Neck Squamous Cell Carcinoma

The Safety and Efficacy of Benmelstobart Injection in Patients With Advanced Biliary Tract Malignant Tumors

PUPA

QL1706

IMMUNOLIFE2

Tislelizumab Combined With Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma Followed by CRT or Surgery

Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma